Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
The Effects of Urinary pH Changes on an Investigational Compound in Healthy Subjects
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2011-09-26
- Last Posted Date
- 2011-10-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT01440478
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri, from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Leeds, United Kingdom
A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma
- Conditions
- Extensive Stage Small Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2011-09-23
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 90
- Registration Number
- NCT01439568
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Richmond, Virginia, United States
A Study of the Effect of Dulaglutide on How Body Handles Digoxin in Healthy Participants
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: DigoxinBiological: Dulaglutide
- First Posted Date
- 2011-09-19
- Last Posted Date
- 2014-10-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT01436201
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Daytona Beach, Florida, United States
A Study in Patients With Type 2 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: LY2605541Drug: Glargine
- First Posted Date
- 2011-09-16
- Last Posted Date
- 2018-04-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1538
- Registration Number
- NCT01435616
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Swansea, Wales, United Kingdom
A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy Participants
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Biological: dulaglutideDrug: Warfarin
- First Posted Date
- 2011-09-13
- Last Posted Date
- 2014-10-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 28
- Registration Number
- NCT01432938
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States
A Study of Enzastaurin in Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma
- First Posted Date
- 2011-09-13
- Last Posted Date
- 2020-10-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 26
- Registration Number
- NCT01432951
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guang Zhou, China
A Relative Bioavailability Study of a Prasugrel Orally Disintegrating Tablet
- Conditions
- Sickle Cell Disease
- Interventions
- First Posted Date
- 2011-09-07
- Last Posted Date
- 2012-11-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 18
- Registration Number
- NCT01430091
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Honolulu, Hawaii, United States
A Study of Teriparatide in Japanese Osteoporosis Patients
- Conditions
- Osteoporosis
- Interventions
- First Posted Date
- 2011-09-07
- Last Posted Date
- 2013-01-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT01430104
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan
A Study of LY2623091 in Male and Females With Chronic Kidney Disease
- First Posted Date
- 2011-09-02
- Last Posted Date
- 2019-09-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 42
- Registration Number
- NCT01427972
- Locations
- 🇿🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pretoria, South Africa
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Biological: Ramucirumab (IMC-1121B)Drug: Eribulin
- First Posted Date
- 2011-09-02
- Last Posted Date
- 2017-02-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 141
- Registration Number
- NCT01427933
- Locations
- 🇺🇸
ImClone Investigational Site, Vancouver, Washington, United States